Patents by Inventor Jeffrey TESTANI,
Jeffrey TESTANI, has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240390566Abstract: Direct sodium removal (“DSR”) therapy methods are provided for removing sodium and reducing fluid overload in patients with renal failure or heart failure, in which a patient has at least first and second DSR treatments with an infusate comprising 15-40 wt % icodextrin and up to 15 wt % dextrose that is instilled into a patient's peritoneal cavity for dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, after which the infusate, sodium and ultrafiltrate is removed from the peritoneal cavity.Type: ApplicationFiled: May 23, 2023Publication date: November 28, 2024Applicant: Sequana Medical NVInventors: Jeffrey TESTANI, Ian CROSBIE, Oliver GOEDJE
-
Publication number: 20240260874Abstract: Embodiments of the present technology can manage a patient's fluid removal based on one or more of the patient's urine output, urine conductivity, urine sodium concentration, and/or urine oxygen content. For example, in some embodiments the patient's urine sodium concentration (and/or an indication thereof including, e.g., the patient's urine conductivity) can be compared to one or more urine sodium concentration thresholds (e.g., a high urine sodium concentration threshold and/or a low urine sodium concentration threshold) to determine one or more adjustments to the patient's therapy such as, e.g., a diuretic dosage rate, a hydration fluid infusion rate, a hydration fluid matching percentage, etc. Additionally or alternatively, the patient's urine oxygen content can be compared to one or more urine oxygen content thresholds (e.g., a high urine oxygen content threshold and/or a low urine oxygen content threshold) to determine one or more adjustments to the patient's therapy.Type: ApplicationFiled: February 6, 2024Publication date: August 8, 2024Inventors: Andrew Halpert, Eric Conley, Jeffrey Testani
-
Publication number: 20240197244Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, and increasing the dosage rate of the diuretic from the initial dosage rate to additional dosage rates higher than the initial dosage rate over a period of time. In some embodiments, the additional dosage rates include a first dosage rate higher than the initial dosage rate, a second dosage rate higher than the first dosage rate, and a third dosage rate higher than the second dosage rate.Type: ApplicationFiled: March 4, 2024Publication date: June 20, 2024Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Publication number: 20240115785Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.Type: ApplicationFiled: December 15, 2023Publication date: April 11, 2024Applicant: Sequana Medical NVInventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
-
Patent number: 11950925Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: GrantFiled: April 5, 2023Date of Patent: April 9, 2024Assignee: REPRIEVE CARDIOVASCULAR, INC.Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Patent number: 11844890Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.Type: GrantFiled: January 20, 2023Date of Patent: December 19, 2023Assignee: Sequana Medical NVInventors: Jeffrey Testani, Christopher McIntyre, Ian Crosbie, Oliver Goedje
-
Publication number: 20230240600Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: ApplicationFiled: April 5, 2023Publication date: August 3, 2023Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Publication number: 20230158221Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.Type: ApplicationFiled: January 20, 2023Publication date: May 25, 2023Applicant: Sequana Medical NVInventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
-
Patent number: 11627912Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: GrantFiled: June 13, 2022Date of Patent: April 18, 2023Assignee: Reprieve Cardiovascular, Inc.Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Patent number: 11559618Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.Type: GrantFiled: May 2, 2022Date of Patent: January 24, 2023Assignee: Sequana Medical NVInventors: Jeffrey Testani, Christopher McIntyre, Ian Crosbie, Oliver Goedje
-
Publication number: 20230010793Abstract: The present technology includes devices, systems, and method for managing a patient's urine output. In some embodiments, an exemplary method includes receiving an estimated amount of excess fluid for the patient; obtaining a urine output rate of the patient; obtaining a diuretic dosage rate of the patient; obtaining (i) a first input corresponding to a percentage of an actual amount of net fluid loss relative to the estimated amount of excess fluid, and/or (ii) a second input corresponding to an estimated amount of fluid remaining; and based on the first input and/or the second input, providing an output associated with adjusting the fluid therapy. Providing the output can include providing an indication with instructions for increasing the patient's urine output by administering an additional diuretic and/or increasing infusion of hydration fluid to the patient.Type: ApplicationFiled: July 12, 2022Publication date: January 12, 2023Inventors: Jeffrey Testani, Andrew Halpert, Kenneth John Luppi, Antony Jonathan Fields, Mark Richard Pacyna, Arslan Mazhar Malik
-
Publication number: 20230001065Abstract: Enhanced systems and methods for performing Direct Sodium Removal (DSR) therapy are provided in which an implantable device includes a variable speed motor-driven pump that may be programmed to output different flow rates at different stages of a DSR therapy session, wherein the system monitors operational parameters of the pump and is configured to generate an alarm condition indicative of a fault that may be displayed on a patient's smartphone to permit corrective action, and in which a catheter set implanted with the implantable device enables a DSR solution may be instilled into the patient's peritoneal cavity using a peritoneal catheter that is subsequently used to remove the DSR solution and sodium-rich ultrafiltrate from the peritoneal cavity to the patient's bladder.Type: ApplicationFiled: September 6, 2022Publication date: January 5, 2023Applicant: Sequana Medical NVInventors: Andreas WIRTH, Jeffrey TESTANI, Ian CROSBIE, Oliver GOEDJE
-
Publication number: 20220313158Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: ApplicationFiled: June 13, 2022Publication date: October 6, 2022Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Publication number: 20220257843Abstract: A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and/or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.Type: ApplicationFiled: May 2, 2022Publication date: August 18, 2022Applicant: Sequana Medical NVInventors: Jeffrey TESTANI, Christopher McINTYRE, Ian CROSBIE, Oliver GOEDJE
-
Publication number: 20220195033Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.Type: ApplicationFiled: November 4, 2021Publication date: June 23, 2022Inventors: Jeffrey TESTANI, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO
-
Patent number: 11357446Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: GrantFiled: December 4, 2020Date of Patent: June 14, 2022Assignee: Reprieve Cardiovascular, Inc.Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Patent number: 11203636Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.Type: GrantFiled: February 1, 2018Date of Patent: December 21, 2021Assignees: YALE UNIVERSITY, Novo Nordisk A/SInventors: Jeffrey Testani, Veena Rao, Rahul Kakkar, Madhav N. Devalaraja, Chih-Hung Lo
-
Publication number: 20210169408Abstract: Devices, systems, and methods for delivering fluid therapy to a patient are disclosed herein. An exemplary method can comprise obtaining a urine output rate from a patient; causing a diuretic to be provided to the patient at a dosage rate, wherein the dosage rate is increased over a period of time such that the urine output rate increases to be above a predetermined threshold within the period of time; and causing a hydration fluid to be provided to the patient at a hydration rate. The hydration rate can be set based on the urine output rate to drive net fluid loss from the patient.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Howard R. Levin, Jim Dillon, Andrew Halpert, Jeffrey Testani
-
Publication number: 20200340031Abstract: The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.Type: ApplicationFiled: December 27, 2018Publication date: October 29, 2020Inventors: Gary Desir, Jeffrey Testani, Veena Rao
-
Publication number: 20200079846Abstract: The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.Type: ApplicationFiled: February 1, 2018Publication date: March 12, 2020Inventors: Jeffrey TESTANI,, Veena RAO, Rahul KAKKAR, Madhav N. DEVALARAJA, Chih-Hung LO